12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AZD5363: Phase I data

Data from a pair of open-label, dose-escalation, European and Japanese Phase I trials in a total of 92 patients showed that twice-daily oral AZD5363 led to 2 partial responses - 1 ovarian cancer patient and 1 cervical cancer patient - plus 1 case of stable disease for 156 days...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >